NASDAQ:CDXC
ChromaDex Corporation Stock News
$3.44
+0.0500 (+1.47%)
At Close: Apr 26, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investigating
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong, available online a
Chromadex: The Little Company That Could
07:38am, Sunday, 08'th Nov 2020
Tru Niagen, CDXC's patented product, shows strong promise in billion dollar markets. Market underestimates monopoly length by ~3x.
ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript
10:42pm, Wednesday, 04'th Nov 2020
ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript
Preview: ChromaDex's Earnings
10:09am, Tuesday, 03'rd Nov 2020
On Wednesday, November 04, ChromaDex (NASDAQ: CDXC) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
ChromaDex to Report Third Quarter 2020 Financial Results on Wednesday, November 4, 2020
06:35am, Wednesday, 28'th Oct 2020
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial r
New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice
12:00am, Monday, 19'th Oct 2020
ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at the effect of
Celltrient™ Cellular Energy Products Featuring Tru Niagen® Launch in US
12:00am, Wednesday, 14'th Oct 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is now available in Nestlé Health Science’s new Celltrient™ Cellul
ChromaDex: Blazing Ahead Of Ponce De Leon (NASDAQ:CDXC)
01:08pm, Sunday, 11'th Oct 2020
Recent study shows nutritional protocol including nicotinamide riboside plus standard of care reduces recovery time by nearly 30%; Phase 3 clinical trial is underway.
New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function
12:00am, Thursday, 08'th Oct 2020
ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor infiltr
ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recovery in mild-to
ChromaDex : to Present at the LD 500 Virtual Investor Conference | MarketScreener
10:33am, Wednesday, 26'th Aug 2020ChromaDex to Present at the LD 500 Virtual Investor Conference
12:00am, Wednesday, 26'th Aug 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting
Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
06:23am, Monday, 24'th Aug 2020
Two Sample Breakout Stocks for Week 35 with better than 10% short-term upside potential. Now up an average 172.2% YTD.
Unity Biotechnology Setback, And Other News: The Good, Bad And Ugly Of Biopharma
01:05pm, Thursday, 20'th Aug 2020
Unity Biotechnology suffers setback for lead drug candidate UBX0101. ChromaDex reports positive Niagen news for heart failure.
